BACKGROUND: Current grading systems in acute graft-versus-host disease (GVHD) are not able to identify patients with poor prognosis at time of onset, because they take into account maximal grade. The aim of this study was to evaluate potential predictors for overall survival at disease onset. METHODS: The study sample was composed of 142 allogeneic hematopoietic stem-cell transplant recipients who developed acute GVHD after a myeloablative conditioning regimen. Factors associated with the risk of nonrelapse mortality (NRM) were analyzed with proportional hazard models. RESULTS: At time of diagnosis, GVHD involved a single organ in the majority of the patients (78%). Initial grade was I in 24%, II or III in 56% of patients. Significant risk factors for NRM were non-HLA matched sibling donor (68% vs. 55%, P=0.05), absence of methotrexate in GVHD prophylaxis (75% vs. 56%, P=0.02), initial liver involvement (80% vs. 56%, P<0.001), time to GVHD more than 24 days (76% vs. 55%, P=0.04), nonhyperacute GVHD (72% vs. 52%, P=0.016), and steroid refractory GVHD (85% vs. 44%, P<0.001). In multivariate analysis, initial liver involvement (hazard ratio 2.45; 95% confidence interval 1.46-4.12) and a non-HLA identical sibling donor (hazard ratio 1.58; 95% confidence interval 1.02-2.43) were independently associated with NRM. CONCLUSION: Initial liver involvement was an important clinical predictor and should be considered in patient management.
BACKGROUND: Current grading systems in acute graft-versus-host disease (GVHD) are not able to identify patients with poor prognosis at time of onset, because they take into account maximal grade. The aim of this study was to evaluate potential predictors for overall survival at disease onset. METHODS: The study sample was composed of 142 allogeneic hematopoietic stem-cell transplant recipients who developed acute GVHD after a myeloablative conditioning regimen. Factors associated with the risk of nonrelapse mortality (NRM) were analyzed with proportional hazard models. RESULTS: At time of diagnosis, GVHD involved a single organ in the majority of the patients (78%). Initial grade was I in 24%, II or III in 56% of patients. Significant risk factors for NRM were non-HLA matched sibling donor (68% vs. 55%, P=0.05), absence of methotrexate in GVHD prophylaxis (75% vs. 56%, P=0.02), initial liver involvement (80% vs. 56%, P<0.001), time to GVHD more than 24 days (76% vs. 55%, P=0.04), nonhyperacute GVHD (72% vs. 52%, P=0.016), and steroid refractory GVHD (85% vs. 44%, P<0.001). In multivariate analysis, initial liver involvement (hazard ratio 2.45; 95% confidence interval 1.46-4.12) and a non-HLA identical sibling donor (hazard ratio 1.58; 95% confidence interval 1.02-2.43) were independently associated with NRM. CONCLUSION: Initial liver involvement was an important clinical predictor and should be considered in patient management.
Authors: Andrew C Harris; James L M Ferrara; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R Couriel; Pavan Reddy; Sophie Paczesny Journal: Blood Date: 2012-01-27 Impact factor: 22.113
Authors: Yoshihiro Inamoto; Paul J Martin; Barry E Storer; Marco Mielcarek; Rainer F Storb; Paul A Carpenter Journal: Haematologica Date: 2013-09-20 Impact factor: 9.941
Authors: S Fuji; K Takano; T Mori; T Eto; S Taniguchi; K Ohashi; H Sakamaki; Y Morishima; K Kato; K Miyamura; R Suzuki; T Fukuda Journal: Bone Marrow Transplant Date: 2014-08-11 Impact factor: 5.483
Authors: Andrew C Harris; Rachel Young; Steven Devine; William J Hogan; Francis Ayuk; Udomsak Bunworasate; Chantiya Chanswangphuwana; Yvonne A Efebera; Ernst Holler; Mark Litzow; Rainer Ordemann; Muna Qayed; Anne S Renteria; Ran Reshef; Matthias Wölfl; Yi-Bin Chen; Steven Goldstein; Madan Jagasia; Franco Locatelli; Stephan Mielke; David Porter; Tal Schechter; Zhanna Shekhovtsova; James L M Ferrara; John E Levine Journal: Biol Blood Marrow Transplant Date: 2015-09-16 Impact factor: 5.742
Authors: Y Arai; J Kanda; H Nakasone; T Kondo; N Uchida; T Fukuda; K Ohashi; K Kaida; K Iwato; T Eto; Y Kanda; H Nakamae; T Nagamura-Inoue; Y Morishima; M Hirokawa; Y Atsuta; M Murata Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Mark T Vander Lugt; Thomas M Braun; Samir Hanash; Jerome Ritz; Vincent T Ho; Joseph H Antin; Qing Zhang; Chee-Hong Wong; Hong Wang; Alice Chin; Aurélie Gomez; Andrew C Harris; John E Levine; Sung W Choi; Daniel Couriel; Pavan Reddy; James L M Ferrara; Sophie Paczesny Journal: N Engl J Med Date: 2013-08-08 Impact factor: 91.245
Authors: Judith Stift; Hideo A Baba; Elisabeth Huber; Birgit Federmann; Hans-Peter Fischer; Annette Schmitt-Graeff; Herrad Baurmann; Wolfgang Bethge; Peter Schirmacher; Fritz Wrba; Hildegard Greinix; Falko Fend; Rainer Schwerdtfeger; Howard M Shulman; Daniel Wolff; Thomas Longerich Journal: Virchows Arch Date: 2014-01-03 Impact factor: 4.535
Authors: C Castilla-Llorente; P J Martin; G B McDonald; B E Storer; F R Appelbaum; H J Deeg; M Mielcarek; H Shulman; R Storb; R A Nash Journal: Bone Marrow Transplant Date: 2014-04-28 Impact factor: 5.483